FDA Approves Imaavy for Generalized Myasthenia Gravis

434 Views

Emedinexus 28 May 2025

On April 29, 2025, the FDA approved Imaavy (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in patients with antibody-positive disease. Imaavy is a monoclonal antibody targeting the neonatal Fc receptor (FcRn), offering a novel immunomodulatory approach for managing this chronic autoimmune condition.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.